Incretin-based therapy for type 2 diabetes mellitus: Pancreatic and extrapancreatic effects

American Journal of Therapeutics

Volumn 20, Issue 4, 2013, Pages 384-393

  Hartman, Israel ^a   Rojas, Edward ^b   Rodríguez Molina, Daloha ^b  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

cell; Incretin; Type 2 diabetes mellitus

Indexed keywords

CJC 1131; CJC 1134; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LY 548806; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PEG DAPD; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MULTICENTER STUDY (TOPIC); NAUSEA; NERVOUS SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE;

EID: 84880850633     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318235f27d     Document Type: Article

References (82)

1. International Diabetes Federation. Diabetes Atlas. 3rd ed; 2006. Available at: http://www.diabetesatlas.org/sites. Brussels, Belgium: International Diabetes Federation. Accessed December 1, 2011.
2. King H, Aubert RE, Herman WH, et al. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
4. Shaw JE, Sicree RA, Zimmet PZ, et al. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
5. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA; 2008. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007. pdf. Accessed July 12, 2011.
6. McFarlane SI, Bahtiyar G. The diabetes epidemic: addressing diagnostic and therapeutic challenges. Therapy. 2011;8:103-104.
7. Hogan P, Dall T, Nikolov P, et al. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
8. Svec F. Incretin physiology and its role in type 2 diabetes mellitus. J Am Osteopath Assoc. 2010;110(7 Suppl 7): eS20-eS24.
9. Kendall DM, Bergenstal RM. Postprandial blood glucose in the management of type 2 diabetes: the emerging role of incretin mimetics. Medscape Diabetes Endocrinol. 2005;7:2.
10. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
11. Fehse F, Trautmann M, Holts JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997.
12. Moore B. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906; 1:28-38.
13. McIntyre N, Holdsworth CD, Turner DS, et al. New interpretation of oral glucose tolerance. Lancet. 1964; 284:20-21.
14. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3-S10.
15. Nauck MA, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
16. Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356-5363.
17. Vilsbøll T, Krarup T, Deacon S, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
18. Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220-224.
19. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med. 2009;122(6 Suppl): S25-S36.
20. Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab. 2008;34 (6 Pt 1):550-559.
21. Tourrel C, Baibe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;50:1562-1570.
22. Stoffers D, Desai B, DeLeon DD, et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003; 52:734-740.
23. Xu G, Stoffers D, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276.
24. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology. 1999;140:778-783.
25. Kim J, Baggio L, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52:751-759.
26. Trümper A, Trümper K, Trusheim H, et al. Glucosedependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15:1559-1570.
27. Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52:124-132.
28. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDK-1) DNA binding activity in b (INS-1)-cells. Diabetologia. 1999;42:856-864.
29. Buteau J, Foisy S, Rhodes CJ, et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes. 2001;50:2237-2243.
30. Trümper A, Trümper K, Horsch D, et al. Mechanisms of mitogenic and anti-apoptotic signaling by glucosedependent insulinotropic polypeptide in b(INS-1)-cells. J Endocrinol. 2002;174:233-246.
31. Hui H, Nourparvar A, Zhao X, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinosiltol 3-kinase-dependent pathway. Endocrinology. 2003;144:1444-1455.
32. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653-2659.
33. Hui H, Wright C, Perfetti R, et al. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. 2001;50:785-796.
34. Bulotta A, Hui H, et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol. 2002;29:347-360.
35. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
36. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471-478.
37. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-5158.
38. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.
39. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552-561.
40. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738-742.
41. Ayala JE, Bracy DP, James FD, et al. Glucagon-like peptide-1 receptor knockout mice are protected from highfat diet-induced insulin resistance. Endocrinology. 2010; 151:4678-4687.
42. Day J, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749-757.
43. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151.
44. Kavianipour M, Ehlers MR, Halberg K, et al. Glucagonlike peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24: 569-578.
45. Thrainsdottir I, Malmberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes Vasc Dis Res. 2004;1:40-43.
46. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
47. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215.
48. Toft-Nielsen MB, Madsbad S, Holst JJ, et al. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22:1137-1143.
49. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
50. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.
51. Moretto T, Milton D, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
52. Zinman B, Gerich J, Bose JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.
53. Mistry G, Maes A, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598.
54. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43-52.
55. Barragan J, Rodríguez R, Blazquez E, et al. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab. 1994;266:E459-E466.
56. Wettergren A, Schojoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38: 665-673.
57. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999;23:304-311.
58. Wang G, Tomasi D, Backus W, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008;39:1824-1831.
59. Kastin A, Akerstrom V, Pan W, et al. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18:7-14.
60. Smeets PA, Vidarsdottir S, de Graaf C, et al. Oral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion. Am J Physiol Endocrinol Metab. 2007;293:E754-758.
61. During M, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173-1179.
62. Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302: 881-888.
63. Perry T, Lahiri D, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-b peptide (Ab) levels and protects hippocampal neurons from death induced by Ab and iron. J Neurosci Res. 2003;72: 603-612.
64. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723.
65. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
66. Deacon CF. Therapeutic strategies based on glucagonlike peptide 1. Diabetes. 2004;53:2181-2189.
67. Agersø H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202.
68. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003; 52:1786-1791.
69. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
70. Marre M, Shaw J, Brandle M, et al. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med. 2009;26:268-278.
71. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
72. Russell-Jones D, Vaag A, Schintz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
73. Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care. 2009;32:1237-1243.
74. Woon C, Taylor J, Dong JZ, et al. BIM 51077, a stable glucagon-like peptide-1 (GLP-1) analogue with preserved gluco-incretin property in vitro. Poster (Abstract P1-359) presented at the Proceedings of the Endocrine Society Meeting, Denver, CO; 2001.
75. Sebokova E, Christ AD, Wang H, et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology. 2010;151: 2474-2482.
76. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402-7405.
77. Ross SA, Ekoé JM. Incretin agents in type 2 diabetes. Can Fam Physician. 2010;56:639-648.
78. Nielsen LL, Young AA, Parkes DG, et al. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.
79. Kolterman O, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62: 173-181.
80. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three doubleblind, placebo-controlled trials. Clin Ther. 2007;29: 139-153.
81. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
82. Daniel DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428-433.